The FDA has approved rivaroxaban (Xarelto) for the prevention of VTE after hip/knee surgery. Depending on pricing, it may be more cost-effective than enoxaparin. Clinical trials (industry-sponsored) have shown a significantly lower rate of VTE post hip/knee in rivaroxaban vs enoxaparin. Past studies evaluating the drug are listed here (abstract) (abstract) (abstract)
Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.